乳腺癌、肺癌和淋巴瘤当代胸部放疗后心血管生物标志物的早期变化
前瞻性纵向研究纳入87例接受光子或质子胸部放疗的乳腺癌、肺癌或纵隔淋巴瘤患者,检测放疗前后心血管生物标志物。肺癌/纵隔淋巴瘤组胎盘生长因子和生长分化因子15显著升高,且与平均心脏剂量、V5和V30相关;乳腺癌组无显著变化。生物标志物变化与超声心动图心功能指标变化无显著关联。
要点
- 乳腺癌患者放疗前后心血管生物标志物无显著升高。
- 肺癌/纵隔淋巴瘤患者胎盘生长因子和生长分化因子15显著升高。
- 平均心脏剂量、V5和V30与放疗后胎盘生长因子和生长分化因子15水平显著相关。
核心结论
- 当代胸部放疗可引起血管和炎症生物标志物的急性异常,且与放射剂量-体积参数相关,尤其在肺癌和纵隔淋巴瘤中。
- 需要长期随访研究以确定这些变化对显性心脏病发展的影响。
研究设计与样本
- 前瞻性纵向研究,纳入87例接受光子或质子胸部放疗的乳腺癌、肺癌或纵隔淋巴瘤患者。
- 放疗前和放疗完成后(中位20天,四分位距1-35天)采集血样,检测高敏心肌肌钙蛋白T、N末端B型利钠肽原、胎盘生长因子和生长分化因子15。
- 采用多变量线性回归模型评估平均心脏剂量、V5和V30与生物标志物水平的关联,以及超声心动图心功能指标与生物标志物水平的关联。
- 分析分为乳腺癌单独组和肺癌与淋巴瘤合并组。
主要发现
- 平均心脏剂量中位数(四分位距):乳腺癌患者(n=60)为1.3 Gy(0.9-2.4),纵隔淋巴瘤患者(n=14)为6.8 Gy(5.4-10.2),肺癌患者(n=13)为8.4 Gy(6.7-16.1)(P < .001)。
- 乳腺癌患者放疗前后生物标志物水平无显著升高。
- 肺癌/淋巴瘤患者胎盘生长因子从放疗前中位数(四分位距)20 ng/L(16-26)升高至放疗后22 ng/L(16-30)(P = .005)。
- 肺癌/淋巴瘤患者生长分化因子15从放疗前1171 ng/L(755-2493)升高至放疗后1887 ng/L(903-3763)(P = .006)。
- 在多变量模型中,平均心脏剂量、V5和V30与放疗后胎盘生长因子和生长分化因子15水平显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要长期随访研究以确定这些变化对显性心脏病发展的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We characterized the early changes in cardiovascular biomarkers with contemporary thoracic radiation therapy (RT) and evaluated their associations with radiation dose-volume metrics including mean heart dose (MHD), V5, and V30. METHODS AND MATERIALS: In a prospective longitudinal study of 87 patients with breast cancer, lung cancer, or mediastinal lymphoma treated with photon or proton thoracic RT, blood samples were obtained pre-RT and after completion of RT (median, 20 days; interquartile range [IQR], 1-35). High-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide, placental growth factor (PIGF), and growth differentiation factor 15 (GDF-15) were measured. Associations between MHD, V5 and V30, and biomarker levels and associations between echocardiography-derived measures of cardiac function and biomarker levels were assessed in multivariable linear regression models. Analyses were performed according to the following subgroups: (1) breast cancer alone and (2) lung cancer and lymphoma combined. RESULTS: The median (IQR) estimates of MHD ranged from 1.3 Gy (0.9-2.4) in breast cancer (n = 60) to 6.8 Gy (5.4-10.2) in mediastinal lymphoma (n = 14) and 8.4 Gy (6.7-16.1) in lung cancer (n = 13) patients (P < .001). There were no significant increases in biomarker levels from pre-RT to post-RT in breast cancer. In lung cancer/lymphoma, PIGF increased from a median (IQR) of 20 ng/L (16-26) to 22 ng/L (16-30) (P = .005), and GDF-15 increased from 1171 ng/L (755-2493) to 1887 ng/L (903-3763) (P = .006). MHD, V5, and V30 were significantly associated with post-RT PIGF and GDF-15 levels in multivariable models. Changes in biomarkers were not significantly associated with changes in echocardiography-derived measures of cardiac function. CONCLUSION: Contemporary thoracic RT induces acute abnormalities in vascular and inflammatory biomarkers that are associated with radiation dose-volume metrics, particularly in lung cancer and mediastinal lymphoma. Long-term follow-up studies are needed to determine the impact of these changes on the development of overt cardiac disease.
引用
- Demissei BG, Freedman G, Feigenberg SJ, et al. Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma. Int J Radiat Oncol Biol Phys. 2018. PMID: 30445173. doi:10.1016/j.ijrobp.2018.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。